北京植德律师事务所 关于西藏易明西雅医药科技股份有限公司 2025 年第二次临时股东会的 法律意见书 植德京(会)字[2025]0129 号 二〇二五年九月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12 th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于西藏易明西雅医药科技股份有限公司 2025 年第二次临时股东会的 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东 资格、网络投票结果均由相应的证券交易所交易系统和互联网投票系统予以认证； 3．本所律师已经按照《股东会规则》的要求，对贵公司本次会议所涉及的 1 法律意见书 植德京(会)字[2025]0129 号 致：西藏易明西雅医药科技股份有限公司（贵公司） 北京植德律师事务 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-061 西藏易明西雅医药科技股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有否决议案的情形。 2、本次股东会没有涉及变更前次股东会决议的议案。 一、会议召开情况： 1、会议通知： 4、会议召集人：公司董事会。 5、会议表决方式：现场记名书面投票与网络投票相结合。 6、现场会议主持人：董事长许可先生。 7、股权登记日：2025 年 9 月 16 日（星期二）。 8、本次股东会召开的时间、地点、方式、召集人、主持人及召集、召开程 序均符合《公司法》《证券法》《深圳证券交易所股票上市规则》等法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 二、会议出席情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"易明医药"） 董事会于 2025 年 9 月 4 日在《证券时报》《上海证券报》和巨潮资讯网 (www.cninfo.com.cn)上刊登了《关于召开 2025 年第二次临时股东会的通知》（以 下简称"股 ...

Core Viewpoint - Yiming Pharmaceutical announced the receipt of a government subsidy amounting to 19,322,657.00 yuan [2] Group 1 - The company received a government subsidy of 19,322,657.00 yuan [2]

Group 1 - The company Yiming Pharmaceutical announced a government subsidy of approximately 19.32 million yuan, which accounts for 42.07% of the audited net profit attributable to shareholders for the fiscal year 2024 [1] - For the first half of 2025, the revenue composition of Yiming Pharmaceutical is as follows: 99.71% from drug sales, 0.58% from other sources, and -0.29% from drug promotion services [1] - As of the report date, Yiming Pharmaceutical has a market capitalization of 3.7 billion yuan [1]

Group 1 - The company Yiming Pharmaceutical (002826) announced on September 16 that it received a government subsidy of 19.32 million yuan [1] - This subsidy accounts for 42.07% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1]

Core Points - Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. received a government subsidy of 19,322,657.00 yuan, which accounts for 42.07% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1] - The subsidy is classified as a revenue-related government grant and is associated with the company's regular business activities, expected to be recognized in the other income for the fiscal year 2025 [1] - The anticipated increase in the company's total profit for 2025 is 19,322,657.00 yuan, although the data is unaudited and the final accounting treatment will depend on the annual audit results [1]

证券代码：002826 证券简称：易明医药 公告编号：2025-060 西藏易明西雅医药科技股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、补助的确认、计量 根据《企业会计准则第16号——政府补助》的规定，公司收到与收益相关的 政府补助时，与企业日常活动相关的政府补助，按照经济业务实质，计入其他收 益或冲减相关成本费用，与企业日常活动无关的政府补助，计入营业外收入。 本次公司收到19,322,657.00元政府补助与收益相关，为与公司日常经营活 动相关的政府补助，计入2025年度其他收益，具体会计处理以年度审计机构审计 结果为准。 3、补助对上市公司的影响 1 一、获取补助的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）近日收到政府补 助19,322,657.00元，占公司2024年度经审计归属于上市公司股东净利润的 42.07%。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府 ...

格隆汇9月16日丨易明医药(002826.SZ)公布，近日收到政府补助19,322,657.00元，占公司2024年度经审 计归属于上市公司股东净利润的42.07%。 ...

证券日报网讯易明医药9月11日在互动平台回答投资者提问时表示，根据中登结算深圳分公司最新下发 的股东名册，截至2025年9月10日，公司股东户数为21，727户。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the news is that Yiming Pharmaceutical has shown significant stock performance, with a year-to-date increase of 91.39% and a recent trading volume indicating active market interest [1] - As of September 10, Yiming Pharmaceutical's stock price reached 19.64 CNY per share, with a total market capitalization of 3.745 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 1.4733 million CNY, with large orders contributing to 15.94% of total buying [1] Group 2 - Yiming Pharmaceutical's main business involves the research, production, and sales of chemical drugs (93.32% of revenue) and traditional Chinese medicine (6.10% of revenue) [1] - The company has been listed on the stock market since December 9, 2016, and has appeared on the trading leaderboard six times this year, with the latest occurrence on August 22, where it recorded a net purchase of 18.41 million CNY [1] - As of August 29, the number of shareholders decreased by 1.87% to 20,800, while the average circulating shares per person increased by 1.91% to 8,381 shares [2] Group 3 - For the first half of 2025, Yiming Pharmaceutical reported a revenue of 311 million CNY, reflecting a year-on-year decrease of 11.52%, and a net profit attributable to shareholders of 37.56 million CNY, down 5.27% year-on-year [2] - Since its A-share listing, the company has distributed a total of 114 million CNY in dividends, with 43.40 million CNY distributed over the past three years [3]